Source comparison
PT-141 Help Erectile Dysfunction Research: Head-to-Head Comparisons
Mechanism of Action Melanocortin-4 receptor agonist. Central nervous system arousal pathway PDE5 inhibitor. Increases cGMP and penile blood flow PDE5 inhibitor. Increases cGMP, longer half-life PT-141 bypasses vascular dysfunction entirely, making it viable fo
This comparison does not assign a generated winner or score.
- Mechanism of Action
- Melanocortin-4 receptor agonist. Central nervous system arousal pathway
- PDE5 inhibitor. Increases cGMP and penile blood flow
- PDE5 inhibitor. Increases cGMP, longer half-life
- PT-141 bypasses vascular dysfunction entirely, making it viable for populations where PDE5 inhibitors are contraindicated or ineffective
- Onset of Action
- 45–60 minutes (peak plasma at 1 hour)
- 30–60 minutes (food delays absorption)
- 30–60 minutes (half-life allows 36-hour window)
- PT-141's onset is comparable, but it doesn't require sexual stimulation to trigger arousal
- Efficacy in Vascular ED
- 60–70% response rate in men with moderate-to-severe vascular dysfunction
- 40–60% response rate in men with severe vascular disease
- 40–60% response rate, similar to sildenafil
- PT-141 shows higher efficacy in populations with vascular comorbidities because the mechanism doesn't rely on arterial dilation
- Contraindications
- Uncontrolled hypertension (transient BP elevation possible)
- Nitrate use, severe cardiovascular disease
- Nitrate use, recent MI or stroke
- PT-141 can be used with nitrates and in men with cardiovascular disease. A critical advantage for older populations
- Side Effect Profile
- Nausea (40% at therapeutic doses), facial flushing, transient BP increase
- Headache (16%), flushing, dyspepsia
- Headache (11%), back pain, myalgia
- PT-141's nausea is dose-dependent and typically resolves within 2–3 hours; PDE5 side effects are milder but more frequent
- Cost Per Dose (2026)
- $45–$80 per injection (compounded sources)
- $8–$15 per tablet (generic sildenafil)
- $10–$20 per tablet (generic tadalafil)
- PT-141 is significantly more expensive, limiting accessibility for long-term use compared to daily or on-demand PDE5 therapy